About CDx Diagnostics
CDx Diagnostics is a company based in Suffern (United States) founded in 1997 by Mark Rutenberg was acquired by Galen Partners in July 2017. CDx Diagnostics has raised $16.04 million across 2 funding rounds from investors including Galen Partners. CDx Diagnostics offers products and services including WATS 3D, OralCDx, and EndoCDx. CDx Diagnostics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and PathAI, among others.
- Headquarter Suffern, United States
- Founders Mark Rutenberg
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.04 M (USD)
in 2 rounds
-
Latest Funding Round
$5 M (USD), Series A
Jun 15, 2020
- Investors
-
Employee Count
Not available
-
Acquired by
Galen Partners
(Jul 11, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CDx Diagnostics
CDx Diagnostics offers a comprehensive portfolio of products and services, including WATS 3D, OralCDx, and EndoCDx.
AI-enabled tool for early detection of precancerous cells in esophagus.
Platform for oral cancer prevention through advanced tissue analysis.
Technology for detecting dysplasia in endoscopic procedures.
People of CDx Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of CDx Diagnostics
CDx Diagnostics has successfully raised a total of $16.04M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CDx Diagnostics
CDx Diagnostics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Galen Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for CDx Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CDx Diagnostics
Investment portfolio details for CDx Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CDx Diagnostics
Detailed financials for CDx Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cdx Diagnostics Comparisons
Peer comparison for CDx Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CDx Diagnostics
CDx Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and PathAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of CDx Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cdx Diagnostics
Complete news archive for CDx Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CDx Diagnostics
CDx Diagnostics was founded in 1997 and raised its 1st funding round 22 years after it was founded.
CDx Diagnostics is headquartered in Suffern, United States. It is registered at Suffern, New York, United States.
CDx Diagnostics is a funded company, having raised a total of $16.04M across 2 funding rounds to date.
CDx Diagnostics was founded in 1997 and is headquartered in Suffern, United States. The company operates in the healthcare diagnostics sector, focusing on AI-driven technologies for early detection of precancerous conditions. Proprietary WATS3D biopsy platform is employed to identify tissue changes. Key products include OralCDx, a non-invasive oral brush biopsy system, and EndoCDx, a transepithelial laryngeal brush biopsy tool, supporting clinical assessments in oncology-related fields.
CDx Diagnostics's top competitors include Juno Therapeutics, Poseida Therapeutics and PathAI.
CDx Diagnostics offers WATS 3D, OralCDx, and EndoCDx.
CDx Diagnostics has 1 investor. Key investors include Galen Partners.